🏛️ Verified NIH Record • Updated 2026-07-10

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial (NCT05077735)

Stereotactic Biopsy Split-Course Radiation Therapy - Diffuse Midline Glioma (SPORT-DMG)

🟢 Recruiting Phase2 🩺 Clinical Procedure Protocol Sponsor: Mayo Clinic

🩺 Plain-English Summary (8th-Grade Level)

This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a difference in the outcome of the treatment, and most importantly, the patients' quality of life.

Who can join: Review the eligibility criteria below.

Location: Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Age range: 1 Year

🧪 Interventions in This Study

  • Hypofractionated Radiation Therapy (RADIATION)
  • Questionnaire Administration (OTHER)
  • Magnetic Resonance Imaging (PROCEDURE)
  • Computed Tomography Scan (PROCEDURE)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • Mayo Clinic in Rochester — Rochester, Minnesota

📞 Contact the Study Coordinator

Phone: (855) 776-0015

Email: mayocliniccancerstudies@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Diffuse Midline Glioma, H3 K27M-Mutant

Explore by condition: All Diffuse Midline Glioma, H3 K27M-Mutant clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗